Skip to main content
Clinical Trials/NCT05293405
NCT05293405
Recruiting
Not Applicable

Neuroinflammatory Imaging Using TSPO PET Tracer in Paients With Autoimmune Encephalomyelitis

Ruijin Hospital1 site in 1 country100 target enrollmentDecember 14, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Autoimmune Encephalomyelitis
Sponsor
Ruijin Hospital
Enrollment
100
Locations
1
Primary Endpoint
TSPO expression level
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Autoimmune encephalomyelitis is a heterogeneous group of central nervous system (CNS) autoimmune diseases characterized by the production of anti-neuron-associated autoantibodies which target neuronal surface proteins, synaptic receptors and intracellular antigens. MRI, as a current first-line imaging tool of CNS inflammation, is difficult to diagnose them because the majority of patients have normal MRI images, and only a few may show local signal or structural abnormalities (including inflammation, edema, or atrophy). The 18 kDa translocator protein (TSPO) expression in the CNS is upregulated in response to microglia activation. DPA-714 is high affinity for binding to TSPO, making 18F-labeled DPA-714 (18F-DPA-714) PET a very promising diagnostic imaging tool for neuroinflammation in patients with autoimmune encephalomyelitis.This study aims to explore the value of 18F-DPA-714 PET in the early diagnosis, therapeutic assessment and prognosis in patients with autoimmune encephalomyelitis.

Registry
clinicaltrials.gov
Start Date
December 14, 2021
End Date
December 31, 2024
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

TSPO expression level

Time Frame: 12 months after baseline

quantitatively assessing the level of neuroinflammation in all brain regions or spinal cord

Study Sites (1)

Loading locations...

Similar Trials